Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 (Anti-OX40 Monoclonal Antibody) in Patients With Advanced/Metastatic Solid Tumor or Lymphoma

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Aug 2023 According to a Shanghai Henlius Biotech media release, the phase 1 clinical trial in advanced/metastatic solid tumours and lymphomas has been approved by the NMPA.
07 Aug 2023 Planned End Date changed from 1 Oct 2024 to 1 Oct 2026.
07 Aug 2023 Planned primary completion date changed from 1 May 2024 to 1 May 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com